TITLE

Keratopathy of Multiple Myeloma Masquerading as Corneal Crystals of Ocular Cystinosis

AUTHOR(S)
Kleta, Robert; Blair, Scott C.; Bernardini, Isa; Kaiser-kupfer, Muriel I.; Gahl, William A.
PUB. DATE
March 2004
SOURCE
Mayo Clinic Proceedings;Mar2004, Vol. 79 Issue 3, p410
SOURCE TYPE
Academic Journal
DOC. TYPE
Report
ABSTRACT
We describe a 49-year-old woman in whom ocular cystinosis was diagnosed on the basis of a routine eye examination 12 years previously. Conjunctival biopsy was reported to support the diagnosis. The patient described photophobia for the past S years and reported a 2-fold increase in her serum IgG level for the past 12 years. On ophthalmic examination, corneal crystals were evident in the epithelium and superficial stromal layers, rather than throughout the cornea! epithelium and the entire stroma as in ocular cystinosis. The patient's serum protein level was elevated at 8.7 g/dL; protein electrophoresis showed an elevated &gama;-globulin peak, and the IgG Level was twice that of normal at 2820 mg/dL. Bone marrow biopsy confirmed the diagnosis of multiple myeloma. This case illustrates that multiple myeloma can mimic cornea! findings of cystinosis.
ACCESSION #
12389784

 

Related Articles

  • Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Moreau, P.; Attal, M.; Garban, F.; Hulin, C.; Facon, T.; Marit, G.; Michallet, M.; Doyen, C.; Leyvraz, S.; Mohty, M.; Wetterwald, M.; Mathiot, C.; Caillot, D.; Berthou, C.; Benboubker, L.; Garderet, L.; Chaleteix, C.; Traullé, C.; Fuzibet, J. G.; Jaubert, J. // Leukemia (08876924);Sep2007, Vol. 21 Issue 9, p2020 

    One hundred de novo multiple myeloma patients with t(4;14) treated with double intensive therapy according to IFM99 protocols were retrospectively analyzed. The median overall survival (OS) and event-free survival (EFS) were 41.4 and 21 months, respectively, as compared to 65 and 37 for patients...

  • Pulmonary and nodal multiple myeloma mimicking lymphoma. P O'Sullivan; N L Müller // British Journal of Radiology;Jul2006, Vol. 79 Issue 943, pe25 

    Multiple myeloma is a haematological malignancy characterized by the occurrence of plasma cell tumours within the bone marrow. In advanced multiple myeloma, metastatic deposits outside the bone marrow (extramedullary) are rare. Reported extramedullary sites include the upper respiratory tract...

  • Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Pour, Ludek; Svachova, Hana; Adam, Zdenek; Almasi, Martina; Buresova, Lucie; Buchler, Tomas; Kovarova, Lucie; Nemec, Pavel; Penka, Miroslav; Vorlicek, Jiri; Hajek, Roman // Annals of Hematology;Apr2010, Vol. 89 Issue 4, p385 

    Angiogenesis plays a significant role in the pathogenesis of multiple myeloma (MM). We have measured concentrations of angiogenesis activators, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor, and hepatocyte growth factor (HGF), and inhibitors, including...

  • Non-Invasive Imaging Provides Spatiotemporal Information on Disease Progression and Response to Therapy in a Murine Model of Multiple Myeloma. Riedel, Simone S.; Mottok, Anja; Brede, Christian; Bäuerlein, Carina A.; Garrote, Ana-Laura Jordán; Ritz, Miriam; Mattenheimer, Katharina; Rosenwald, Andreas; Einsele, Hermann; Bogen, Bjarne; Beilhack, Andreas // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    Background: Multiple myeloma (MM) is a B-cell malignancy, where malignant plasma cells clonally expand in the bone marrow of older people, causing significant morbidity and mortality. Typical clinical symptoms include increased serum calcium levels, renal insufficiency, anemia, and bone lesions....

  • Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells. Lamorte, S; Ferrero, S; Aschero, S; Monitillo, L; Bussolati, B; Omedè, P; Ladetto, M; Camussi, G // Leukemia (08876924);May2012, Vol. 26 Issue 5, p1081 

    Angiogenesis is considered a hallmark of multiple myeloma (MM) progression. In the present study, we evaluated the morphological and functional features of endothelial cells (ECs) derived from bone marrow (BM) of patients affected by MM (MMECs). We found that MMECs compared with normal BM ECs...

  • Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Dimopoulos, M. A.; Chen, C.; Spencer, A.; Niesvizky, R.; Attal, M.; Stadtmauer, E. A.; Petrucci, M. T.; Yu, Z.; Olesnyckyj, M.; Zeldis, J. B.; Knight, R. D.; Weber, D. M. // Leukemia (08876924);Nov2009, Vol. 23 Issue 11, p2147 

    We present a pooled update of two large, multicenter MM-009 and MM-010 placebo-controlled randomized phase III trials that included 704 patients and assessed lenalidomide plus dexamethasone versus dexamethasone plus placebo in patients with relapsed/refractory multiple myeloma (MM). Patients in...

  • Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Sagaster, V.; Ludwig, H.; Kaufmann, H.; Odelga, V.; Zojer, N.; Ackermann, J.; Küenburg, E.; Wieser, R.; Zielinski, C.; Drach, J. // Leukemia (08876924);Jan2007, Vol. 21 Issue 1, p164 

    Studies of bortezomib in patients with relapsed multiple myeloma (MM) suggested that bortezomib may be active even in the presence of adverse prognostic factors. We therefore evaluated 62 patients with relapsed/refractory MM who were treated with single-agent bortezomib, and addressed the...

  • Auer Rod--like Inclusions in Immunoglobulin A Multiple Myeloma. V., Mahesha; Hal, Munita Meenu; Varma, Neelam; Sakhuja, Vinay // Archives of Pathology & Laboratory Medicine;May2005, Vol. 129 Issue 5, p706 

    The article focuses on multiple myeloma. A 50-year-old woman was under investigation for pyrexia of unknown origin. Based on physical examination, a diagnosis of Immunoglobulin A multiple myeloma was offered. Ultrastructural analysis of plasma cells showed Auer rod-like inclusions with a smooth...

  • Myeloma in a very young woman presenting with bone pain. Dubrey, Simon W.; Patel, Ketan // British Journal of Hospital Medicine (17508460);Jan2008, Vol. 69 Issue 1, p48 

    A case study of a 29-year-old woman diagnosed with multiple myeloma is presented. This is generally considered to be a disease of those in their late middle age or latter years. In this context, the author described the epidemiology, diagnosis and management of this condition. The diagnosis is...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics